Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 1, 1998, Pages 142-149

  Snoeck, Eric ^a   Ver Donck, Kris ^a   Jacqmin, Philippe ^a   Van Belle, Herman ^a   Dupont, Alain G ^a   Van Peer, Achiel ^a   Danhof, Meindert ^b  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DRAFLAZINE;

ARTICLE; CATABOLISM; CONCENTRATION RESPONSE; DEAMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; ENERGY METABOLISM; ERYTHROCYTE MEMBRANE; HOMEOSTASIS; HUMAN; HUMAN CELL; NUCLEOTIDE METABOLISM; PHARMACODYNAMICS; PRIORITY JOURNAL; RECEPTOR OCCUPANCY;

ADENOSINE; CARRIER PROTEINS; ERYTHROCYTES; HUMANS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; NUCLEOSIDE TRANSPORT PROTEINS; PIPERAZINES;

EID: 15444356378     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Agarwal RP, Spector T and Parks RE (1977) Tight-binding inhibitors IV. Inhibition of adenosine deaminase by various inhibitors. Biochem Pharmacol 26:359-367.
2. Agarwal RP and Parks RE (1978) Adenosine deaminase from human erythrocytes. Methods Enzymol 51:502-517.
3. Belardinelli L, Linden J and Berne RM (1989) The cardiac effects of adenosine. Prog Cardiovasc Dis 32:73-97.
4. Beukers MW, Kerkhof CJM, Ijzerman AP and Soudijn W (1994) Nucleoside transport inhibition and platelet aggregation in human blood: R75251 and its enantiomers draflazine and R88016. Eur J Pharmacol 266:57-62.
5. Böhm M, Weinhold C, Schwinger RHG, Müller-Ehmsen J, Böhm D, Reichenspurner H, Reichart B and Erdmann E (1994) Studies of the nucleoside transport inhibitor, draflazine, in the human myocardium. Br J Pharmacol 112:137-142.
6. D'Argenio DZ and Schumitzky A (1979) A program package for simulation and Parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115-134.
7. D'Argenio DZ, Schumitzky A and Wolf W (1988) Simulation of linear compartment models with application to nuclear medicine kinetic modeling. Comput Methods Programs Biomed 27:47-54.
8. D'Argenio DZ and Schumitzky A (1990) ADAPT II User's Guide. Biomedical Simulations Resource, University of Southern California, Los Angeles.
9. Engler RL (1991) Adenosine. The signal of life? Circulation 84:951-955.
10. Ely SW and Berne RM (1992) Protective effects of adenosine in myocardial ischaemia. Circulation 85:893-904.
11. Klabunde RE (1983) Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol 83:21-26.
12. Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56:248-252.
13. Nees S (1989a) Coronary flow increases induced by adenosine deaminase and adenine nucleotides are mediated by the coronary endothelium: a new principle of the regulation of coronary flow. Eur Heart J 10:28-35.
14. Nees S (1989b) The adenosine hypothesis of metabolic regulation of coronary flow in the light of newly recognized properties of the coronary endothelium. Z Kardiol 78(suppl 6):42-49.
15. Newby AC (1984) Adenosine and the concept of "retaliatory metabolites." Trends Biochem Sci 9:42-44.
16. Plagemann PGW and Wohlhueter RM (1985) Adenine nucleotide metabolism and nucleoside transport in human erythrocytes under ATP depletion conditions. Biochim Biophys Acta 778:176-184.
17. Plagemann PGW, Wohlhueter RM and Kraupp M (1985) Adenosine uptake, transport, and metabolism in human erythrocytes. J Cell Physiol 125:330-336.
18. Schrader J (1990) Adenosine. A homeostatic metabolite in cardiac energy metabolism. Circulation 81:389-391.
19. Schrader WP and West CA (1990) Localization of adenosine deaminase and adenosine deaminase complexing protein in rabbit heart. Cire Res 66:754-762.
20. Segal HL (1959) The development of enzyme kinetics, in The enzymes (Boyer PD, Lardy H and Myrbäck K, eds) 2nd ed, pp 1-48, Academic Press, New York.
21. Smolenski RT, Suitters A and Yacoub MH (1992) Adenine nucleotide catabolism and adenosine formation in isolated human cardiomyocytes. J Mol Cell Cardiol 24:91-96.
22. Snoeck E, Jacqmin P, Van Peer A, Danhof M, Ver Donck K, Van Belle H, Woestenborghs R, Crabbé R, Van Gool R, Dupont A and Heykants J (1996) The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. Br J Clin Pharmacol 42:605-613.
23. Snoeck E, Piotrovskij V, Jacqmin P, Van Peer A, Danhof M, Ver Donck K, Woestenborghs R, Van Belle H, Van Bortel L, Van Gool R, Dupont A and Heykants J (1997a) Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. Br J Clin Pharmacol 43:603-612.
24. Snoeck E, Piotrovskij V, Jacqmin P, Van Peer A, Woestenborghs R, Van Gool R, Dupont A and Heykants J (1997b) Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations. Eur J Clin Pharmacol 53:57-63.
25. Sollevi A (1986) Cardiovascular effects of adenosine in man: Possible clinical implications. Prog Neurobiol 27:319-349.
26. Stoeckler JD, Agarwal RP, Agarwal KC and Parks RE (1978) Purine nucleoside phosphorylase from human erythrocytes. Methods Enzymol 51:530-538.
27. Van Belle H (1969) Uptake and deamination of adenosine by blood: species differences, effects of pH, ions, temperature and metabolic inhibitors. Biochim Biophys Acta 192:124-132.
28. Van Belle H, Wynants J, Xhonneux R and Flameng W (1986) Changes in creatinine phosphate, inorganic phosphate, and the purine pattern in dog hearts with time of coronary artery occlusion and effect thereon of mioflazine, a nucleoside transport inhibitor. Cardiovasc Res 20:658-664.
29. Van Belle H, Goossens F and Wynants J (1987) Formation and release of purine catabolites during hypoperfusion, anoxia and ischemia. Am J Physiol 252:H886-H893.
30. Van Belle H, Goossens F and Wynants J (1989) Biochemical and functional effects of nucleoside transport inhibition in isolated cat heart. J Mol Cell Cardiol 21:797-805.
31. Van Belle H and Janssen PAJ (1991) Comparative pharmacology of nucleoside transport inhibitors. Nucleosides Nucleotides 10:975-982.
32. Van Belle H, Wynants J and Ver Donck K (1991) Comparison of the existing transport inhibitors: In vitro and in vivo data, in Purine and Pyrimidine Metabolism in Man (Harkness RA, Elion GB, Zöllner N, eds), VII, Part A, pp 419-422, Plenum Press, New York.
33. Van Belle H (1993a) Nucleoside transport inhibition: A therapeutic approach to cardioprotection via adenosine. Cardiovasc Res 27:68-76.
34. Van Belle H (1993b) Adenosine promoters: an overview of existing strategies. Curr Opin Invest Drugs 2:1191-1199.
35. Van Belle H (1993c) Nucleoside transport inhibition for cardioprotection: new perspectives for the clinic. Drug Dev Res 28:344-348.
36. Van Belle H (1994) Specific metabolically active anti-ischemic agents: adenosine and nucleoside transport inhibitors, in Cardiovascular Pharmacology and Therapeutics (Singh BN, Dzan VJ, Vanhoutte PM, Woosley RL, eds) pp 217-235, Churchill Livingstone, New York.
37. Ver Donck K, Verheyen WLJ and Van Belle H (1991) Nucleoside transport inhibition and fMLP-stimulated whole blood luminescence. J Mol Cell Cardiol 23:783-785.
38. Ver Donck K (1994) Purine metabolism in the heart. Strategies for protection against myocardial infarction. Pharm World Sci 16:69-76.
39. Wainwright CL, Parratt JR and Van Belle H (1993) The antiarrhythmic effects of the nucleoside transport inhibitor, R75231, in anaesthetized pigs. Br J Pharmacol 109:592-599.
40. Wigler PW and Alberty RA (1960) J Am Chem Soc 82:482-5488.
41. Wynants J and Van Belle H (1985) Single-run high performance liquid chromatography of nucleotides, nucleosides and major purine bases and its application to different tissue extracts. Anal Biochem 144:258-264.